Skip to content
RecruitingN/A

Longitudinal Assessment of Biomarkers Among Patients With MDD

NCT07931001 · Massachusetts General Hospital

Recruiting
Status
Accepting participants
Not applicable
Phase
100
Target enrolment
1
Study sites
1 US states

What it is testing

Summary

This prospective observational study will evaluate whether speech collected through a smartphone application can be used to assess depressive symptom severity and detect symptom changes among adults with major depressive disorder receiving ketamine, esketamine, or infliximab. Up to 100 participants will complete brief speech tasks and self-report measures of depression, anxiety, and insomnia at baseline, week 2, and week 4. Clinician-rated depression severity will be assessed at baseline and week 4. Optional passive smartphone data, including activity and sleep measures, may also be collected. The study will examine the agreement between speech-based model predictions and established clinical assessments, as well as the ability of the model to identify symptom severity and treatment response. The study is observational and will not alter participants' clinical treatment. By evaluating remote speech-based assessments alongside optional passive behavioral monitoring, this research may support more effective measurement-based care and improve the evaluation and management of depression in clinical settings.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Montgomery Åsberg Depression Rating Scale (MADRS)

    Measured over From baseline to Week 4

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * Clinical diagnosis of MDD confirmed via chart review * Aged 18 years or older * Fluent in reading and speaking English * Capable of providing informed consent and complying with the protocol in the estimation of the investigator. * Capable of operating the Callyope app * Capable of completing speech tasks * Owning a smartphone Exclusion Criteria: * Meeting DSM-5 criteria for any psychotic disorder (e.g., schizophrenia or delusional disorder) or a substance use disorder (excluding mild alcohol and cannabis use disorder, which will be permitted).

Where

1 study site

FacilityCityRegionCountry
Depression Clinical Research ProgramBostonMassachusettsUnited States

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record. The registry also holds the most current version of everything above.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT07931001 on ClinicalTrials.gov →

Last updated in the registry 2026-11-12. Registry records change; this page reflects the data build of 2026-11-17.

Related

Where this trial sits